Ocugen (OCGN) Competitors

Immunome (NASDAQ:IMNM) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, community ranking, media sentiment, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.

Does the MarketBeat Community believe in IMNM or OCGN?

Ocugen received 79 more outperform votes than Immunome when rated by MarketBeat users. However, 74.42% of users gave Immunome an outperform vote while only 70.70% of users gave Ocugen an outperform vote.

Company	Underperform	Outperform
Immunome	Outperform Votes 32 74.42%	Underperform Votes 11 25.58%
Ocugen	Outperform Votes 111 70.70%	Underperform Votes 46 29.30%

Is IMNM or OCGN more profitable?

Ocugen has a net margin of -532.51% compared to Immunome's net margin of -3,014.59%. Immunome's return on equity of -48.63% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunome	-3,014.59%	-48.63%	-41.62%
Ocugen	-532.51%	-154.75%	-90.79%

Which has more volatility and risk, IMNM or OCGN?

Immunome has a beta of 1.9, meaning that its share price is 90% more volatile than the S&P 500. Comparatively, Ocugen has a beta of 3.82, meaning that its share price is 282% more volatile than the S&P 500.

Which has higher valuation and earnings, IMNM or OCGN?

Ocugen has lower revenue, but higher earnings than Immunome. Ocugen is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$10.13M	75.07	-$106.81M	-$8.11	-1.18
Ocugen	$6.04M	32.80	-$63.08M	-$0.18	-3.78

Do insiders and institutionals hold more shares of IMNM or OCGN?

44.6% of Immunome shares are owned by institutional investors. Comparatively, 10.3% of Ocugen shares are owned by institutional investors. 8.6% of Immunome shares are owned by company insiders. Comparatively, 4.3% of Ocugen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Do analysts recommend IMNM or OCGN?

Immunome currently has a consensus price target of $28.60, suggesting a potential upside of 200.07%. Ocugen has a consensus price target of $6.00, suggesting a potential upside of 782.35%. Given Ocugen's higher possible upside, analysts plainly believe Ocugen is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Ocugen	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media refer more to IMNM or OCGN?

In the previous week, Ocugen had 6 more articles in the media than Immunome. MarketBeat recorded 7 mentions for Ocugen and 1 mentions for Immunome. Immunome's average media sentiment score of 1.82 beat Ocugen's score of 1.24 indicating that Immunome is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunome	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Ocugen	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Immunome beats Ocugen on 10 of the 17 factors compared between the two stocks.